» Articles » PMID: 15772904

Role of Ovary and Adrenal Glands in Hyperandrogenemia in Patients with Polycystic Ovary Syndrome

Overview
Specialty Endocrinology
Date 2005 Mar 18
PMID 15772904
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Ovary is the main source of the hyperandrogenism in polycystic ovary syndrome (PCOS). Adrenal glands may also be involved in the pathogenesis of the development of PCOS. To investigate this possibility and to find out if buserelin test is able to distinguish PCOS patients from the patients with idiopathic hirsutism (IH), ACTH and buserelin tests were performed in 29 women with PCOS, 21 women with IH, and 20 control subjects (CS). We also aimed to determine the role of dysregulation of 17 hydroxylase in the development of PCOS. Basal and stimulated dehydroepiandrosterone sulfate (DHEA-S) and stimulated cortisol (F) levels after ACTH administration were significantly higher in PCOS group than in IH and CS groups (p<0.0001 and p<0.05, respectively). PCOS patients also possessed significantly higher basal and stimulated 17-hydroxyprogesterone (17-OH P) levels, including the peak levels (p<0.02), during buserelin testing when compared with IH patients and CS. There was no significant correlation between the ACTH-stimulated and the buserelin-stimulated peak 17-OH P values. In conclusion, significantly higher basal and ACTH-stimulated levels of F and DHEA-S in PCOS compared with controls and patients with IH, reflect that adrenal hyperactivity also plays a role in hyperandrogenemia seen in PCOS. Because of the lack of the correlation between ACTH-stimulated and buserelin-stimulated 17-OH P levels, it is hard to say that adrenal hyperactivity seen in PCOS is the result of the dysregulation of cytochrome P450c17-alpha enzyme. Our results suggest that buserelin test which is an GnRH analogue could distinguish at least some of the patients with PCOS from the other patients presenting with the common symptoms of hyperandrogenemia.

Citing Articles

A case-control study about markers of stress in normal-/overweight women with polycystic ovary syndrome and in controls.

Marschalek M, Marculescu R, Schneeberger C, Marschalek J, Dewailly D, Ott J Front Endocrinol (Lausanne). 2023; 14:1173422.

PMID: 37265693 PMC: 10231031. DOI: 10.3389/fendo.2023.1173422.


PCOS in adolescence and type 2 diabetes.

Carreau A, Baillargeon J Curr Diab Rep. 2014; 15(1):564.

PMID: 25398203 DOI: 10.1007/s11892-014-0564-3.


Adrenocortical production is associated with higher levels of luteinizing hormone in nonobese women with polycystic ovary syndrome.

Tock L, Carneiro G, Pereira A, Tufik S, Zanella M Int J Endocrinol. 2014; 2014:620605.

PMID: 24895496 PMC: 4033536. DOI: 10.1155/2014/620605.


Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome.

Cinar N, Harmanci A, Yazgan Aksoy D, Aydin K, Yildiz B J Ovarian Res. 2012; 5(1):42.

PMID: 23216997 PMC: 3523978. DOI: 10.1186/1757-2215-5-42.